Cell and gene therapy CRO market, Size and Share by 2035

The “Cell and Gene Therapy CROs Market, 2022-2035” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade.

Roots Analysis is pleased to announce the publication of its recent study, titled, “Cell and Gene Therapy CROs Market, 2022-2035”.

Key Inclusions
 A detailed overview of the overall market landscape of the cell and gene therapy CROs, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, area of expertise (cell therapy (stem cells, T cells, dendritic cells, NK cells and tumor cells) and gene therapy), scale of operation (discovery, preclinical, clinical and commercial) and types of services offered, including [A] preclinical services (bioanalytical services, in-vivo studies, pharmacokinetic and ADME services, preclinical safety studies, toxicology studies and other preclinical services), [B] clinical services (clinical research monitoring, clinical trial management/ clinical project management, data management, safety and pharmacovigilance, and other clinical services), [C] regulatory services (GAP analysis, IND preparation, legal representation and technical dossier submission) and [D] general support services (biostatistics, consulting, post-market assessment, re-imbursement and training).
 A detailed analysis on the business models that are commonly adopted by the biopharmaceutical industry for outsourcing cell and gene therapies. In addition, it includes information on various factors that drive developers towards outsourcing and key parameters that sponsors must consider while choosing CROs at each phase of drug development process.
 Elaborate profiles of key industry players (very large and large companies) based in North America, Europe and Asia-Pacific that offer contract research services for both cell and gene therapies across both preclinical and clinical scales of operation. Each profile features a brief overview of the company, along with details related to its cell and gene therapies-related service portfolio, recent developments, and an informed future outlook.
 A benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies (in terms of their expertise across various services related to the development of cell and gene therapies). The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to gain a competitive edge in the industry.
 An analysis of the recent collaborations within the cell and gene therapy contract research industry, based on several relevant parameters, such as year of partnership, type of partnership, area of expertise, most active players (in terms of number of deals inked) and regional distribution of partnership activity that have been undertaken in this domain, during the period 2015-2022.
 A detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2015-2022, based on several parameters, such as year, type of agreement, area of expertise, geographical location of the companies and key value drivers.
 A detailed acquisition target analysis, taking into consideration historical trend of the activity of players that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.
 A list of over 310 cell therapy developers that are anticipated to partner with cell therapy CROs. These players have been shortlisted based on several relevant parameters, such as developer strength (based on company's size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), and availability of other cell therapy capabilities.
 An in-depth analysis of nearly 235 gene therapy developers that are anticipated to partner with gene therapy CROs and have been shortlisted on the basis of several relevant parameters, such as developer strength (based on company's size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other gene therapy capabilities.
 An in-depth analysis of completed, ongoing, and planned clinical studies of various cell and gene therapies, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), therapeutic area and key geographical regions.
 A detailed analysis of the total cost of ownership for large / very large cell and gene therapy contract research organizations. It features an informed estimate of direct and indirect expenses taking into consideration various relevant parameters, over a span of 20 years.
 A detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry's evolution highlighting the relative effect of each SWOT parameter on the overall cell and gene therapies research services industry.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
 Area of Expertise
 Cell Therapy
 Gene Therapy

 Scale of Operation
 Preclinical
 Clinical
 Drug Discovery

 Therapeutic Area
 Oncological Disorders
 Neurological Disorders
 Cardiovascular Disorders
 Infectious Diseases
 Metabolic Disorders
 Autoimmune Disorders
 Blood Disorders
 Rare / Genetic Disorders
 Ophthalmic Disorders
 Other disorders

 Analysis by Geographical Regions
 North America
 Europe
 Asia Pacific
 Latin America
 Middle East and North Africa

Key Questions Answered
 Who are the leading players engaged in offering cell and gene therapy related research services?
 Which business models are most commonly adopted by biopharmaceutical developers for outsourcing cell and gene therapies?
 Which partnership models are commonly adopted by stakeholders engaged in this industry?
 What are the key value drivers of the merger and acquisition activity in the cell and gene therapy market?
 Which players are likely to partner with cell and gene therapy CROs?
 Which regions emerged as the key hubs for carrying out clinical studies focused on cell and gene therapies?
 How is the current and future market opportunity likely to be distributed across key market segments?
 What are the anticipated future trends related to cell and gene therapy related research services?

To view more details on this report, click on the link:
[a]https%3A%2F%2Fwww.rootsanalysis.com%2Freports%2Fview_document%2Fcell-and-gene-therapy-cros-market%2F230.html[/a]

You may also be interested in the following titles:
3D Bioprinting

Digital Therapeutics Market


You may also like to learn what our experts are sharing in Roots educational series:
mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends

Novel Cell Cytometers: Need of the Hour


About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

#cellandgenetherapycromarkettrends #cellandgenetherapycromarketshare #atmps #genetherapycro #cellandgenetherapycompanies

Digital Twins market Professional Survey Report by 2035

Given the potential of digital twins to replicate the physical world in a digital layout, as well as their ability to provide real-time outputs, while gathering constant inputs from the real-world, such products have generated significant interest within the healthcare domain

The USD 29.8 billion (by 2035) financial opportunity within digital twins market has been analyzed across the following segments:
 Therapeutic Area
 Cardiovascular Disorders
 Metabolic Disorders
 Orthopedic Disorders
 Other Disorders

 Type of Digital Twin
 Process Twins
 System Twins
 Whole Body Twins
 Body Part Twins

 Area of Application
 Asset / Process Management
 Personalized Treatment
 Surgical Planning
 Diagnosis
 Other Applications

 End Users
 Pharmaceutical Companies
 Medical Device Manufacturers
 Healthcare Providers
 Patients
 Other End Users

 Key Geographical Regions
 North America
 Europe
 Asia
 Latin America
 Middle East and North Africa
 Rest of the World

The Digital Twins Market, 2022-2035, report features the following companies, which we identified to be key players in this domain:
 Babylon
 ExactCure
 ImmersiveTouch
 Navv Systems
 ThoughtWire
 Unlearn.AI

The latest report also provides key insights for Digital Twins Technology and Digital Twins Providers

Table of Contents
1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Key Insights

6. Company Competitiveness Analysis

7. Company Profiles

8. Partnerships and Collaborations

9. Funding and Investments Analysis

10. Berkus Start-up Valuation Analysis

11. Market Forecast

12. Conclusion

13. Executive insights

14. Appendix I: Tabulated data

15. Appendix II: List of Companies and Organizations

Get more details on the Digital Twins Market report https://www.rootsanalysis.com/....reports/digital-twin

You may also be interested in the following titles:
Non-Viral / Intracellular Drug Delivery Systems Market

Dental 3D Printing Market


You may also like to learn what our experts are sharing in Roots educational series:

At-home Self-testing: A Giant Leap Towards Transformation in Diagnostic Sector

SARM1: A Potential Therapeutic Target For Neurodegenerative Diseases


About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

#digitaltwinsmarket #digitaltwinsmarketgrowth #digitaltwins #digitaltwinmarketsize #digitaltwintechnologycompanies

Satta King 786 | Casino Game 2023
https://sattakingm.in/
https://sattakingg.in/

Satta King 786 is one of the oldest games in India. It is a lottery game that has been around for centuries. It is a great way to make some extra money. However, it is important to know the rules of the game before you play.
Gali Satta is a game of chance, so it is not guaranteed that you will win. However, there are some tips that you can follow to improve your chances of winning.

 

sattakingm.in

Satta king 2023 | Sattaking | Satta result | Satta king online | Satta king live | Satta king result

Get 2023 - Satta King, satta result, satta king up, sattaking, gali result, satta result up, black satta, satta king 786, satta gali, satta king gali, desawar result, faridabaad result, gaziabaad result king

Latest news on CAR-T Cell Therapy market Research Report by 2035


The “Global CAR-T Cell Therapy Market (4th Edition), 2022-2035 report features an extensive study of the current market landscape and future potential of CAR-T therapies over the next decade.

Key Inclusions
 A detailed assessment of the current market landscape of CAR-T-cell immunotherapies with respect to type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19 / CD22, GPC3, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR-T cell therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific).
 An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
 A detailed analysis of completed, ongoing and planned clinical studies related to CAR-T cell therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
 An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-T cell therapies, considering them to be KOLs, who are actively involved in R&D of CAR-T cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
 Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
 An analysis of various type of partnership that have been inked between several stakeholders in the domain of CAR-T-cell therapies, covering various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
 An analysis of the investments that have been made into companies that have proprietary CAR-T cell-based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
 An in-depth analysis of patents related to CAR-T cell therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
 A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
 An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR-T cell based immunotherapy that is likely to be marketed in the coming years.
 A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies, namely Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™.
 Elaborate profiles of the several leading players in the domain of CAR-T cell therapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T cell therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.
 The projected opportunity within the CAR-T cell therapies market is expected to be well distributed across key / emerging players and different geographical regions

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

 Target Indication(s)
 Non-Hodgkin’s Lymphoma
 Multiple Myeloma
 Acute Lymphoblastic Leukemia
 Chronic Lymphocytic Leukemia
 Hodgkin’s Lymphoma
 Acute Myeloid Leukemia
 Ovarian Cancer
 Generalized Myasthenia Gravis (MG)
 Renal Cell Carcinoma

 Target Antigen
 CD19
 BCMA
 CD19/22
 Others

 Key Geographical Regions
 North America
 Europe
 Asia Pacific
 Latin America
 Middle East and North Africa
 Rest of the World

Key Questions Answered
 What are the prevalent R&D trends related to CAR-T cell therapies?
 What are the clinical conditions can be treated using CAR-T cell therapies?
 Who are the leading industry and non-industry players in this market?
 In which geographies, extensive research on CAR-T cell therapy is being conducted?
 What kind of partnership models are commonly adopted by industry stakeholders?
 Who are the key investors in the CAR-T cell immunotherapy domain?
 Who are the key opinion leaders / experts from renowned academic and research institutes which can help drive product development efforts in this domain?
 How is the intellectual property landscape for global CAR-T cell therapies likely to evolve in the foreseen future?
 Who are the key service providers (CMOs / CDMOs) with capabilities to develop and manufacture CAR-T cell therapies?
 What are the key factors that are likely to influence the evolution of the CAR-T cell immunotherapies market?
 How is the current and future market opportunity likely to be distributed across key market segments?
 What are the key promotional strategies used by companies having marketed products?

Get more details on the CAR-T Cell Therapy Market report https://www.rootsanalysis.com/....reports/view_documen

You may also be interested in the following titles:
DNA Encoded Libraries
Quantum Computing in Drug Discovery Services Market

You may also like to learn what our experts are sharing in Roots educational series:
CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications

At-home Self-testing: A Giant Leap Towards Transformation in Diagnostic Sector


About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

#cartcelltherapymarkettrends #cartcelltherapymarketanalysis #cartimmunotherapies #cart #cartcellbasedproducts